Syndax Pharmaceuticals Inc: insider trades · United States · SEC (Form 4)

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq under the ticker SNDX, trading on the United States equity market. For French-speaking investors, Syndax is best viewed as a commercial-stage oncology specialist rather than a pure early-stage biotech. The company focuses on innovative therapies for hematologic cancers and related indications, and it now has two FDA-approved medicines alongside a broader clinical pipeline designed to expand the addressable market for those assets. Its principal office is in New York, after the company closed its Waltham, Massachusetts office in early 2025. Syndax was incorporated in Delaware in 2005, giving it a meaningful operating history even though its transition into a commercial company is relatively recent. The investment case is anchored by two lead products. Revuforj (revumenib) is an oral, first-in-class menin inhibitor. It received FDA approval in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation, and in October 2025 the FDA approved it for another AML population with a susceptible NPM1 mutation. This second approval materially broadens the commercial and clinical opportunity. Niktimvo (axatilimab-csfr), developed with Incyte, is another approved therapy used in chronic graft-versus-host disease (GVHD). Together, these products move Syndax from a development story to a company with real commercial execution risk and upside, as value creation increasingly depends on prescription uptake, launch quality, label expansion, and sustained evidence generation. Competitively, Syndax remains a niche player versus large pharmaceutical companies, but it has a differentiated scientific profile in hematology-oncology. Its positioning is supported by targeted mechanisms, regulatory designations, and a meaningful development program around expanding approved uses. From a geographic standpoint, commercial activity is primarily U.S.-centered, while the clinical and scientific footprint is international through major hematology and oncology congresses. Recent developments are especially important. In 2025, Syndax presented multiple clinical datasets for Revuforj and Niktimvo, secured FDA Priority Review for a Revuforj supplemental filing, and then achieved the October 2025 FDA approval that expanded Revuforj into a second AML patient population. The company also reported accelerating commercial revenue in 2025, underscoring the transition from pipeline optionality to launch execution. For investors, Syndax is a high-growth oncology name where commercial traction, regulatory follow-through, and future indication expansion are the key catalysts.